| 2026-08-21 16:42 |
8-K |
["5.02", "9.01"] |
officer change |
0.52
|
CEO termination and interim replacement with strategic partnership executive; weak M&A signal without explicit transaction language. |
SEC · detail |
| 2026-08-17 08:15 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine quarterly earnings release with no M&A-related content or signals. |
SEC · detail |
| 2026-08-05 17:00 |
8-K |
["5.07", "9.01"] |
other |
0.15
|
Routine annual shareholder meeting results; no M&A signals detected. Failed proposals suggest governance challenges. |
SEC · detail |
| 2026-07-29 17:25 |
8-K |
["5.02", "9.01"] |
officer change |
0.25
|
CEO employment agreement renewal with standard severance; Change of Control provisions present but routine for executive retention. |
SEC · detail |
| 2026-07-09 16:15 |
8-K |
["8.01"] |
other |
0.05
|
Annual meeting postponement to solicit proxies; routine administrative matter unrelated to M&A. |
SEC · detail |
| 2026-07-02 17:15 |
8-K |
["5.02"] |
officer change |
0.25
|
Board member resignation citing personal matters and other business ventures; no M&A indication. |
SEC · detail |
| 2026-06-17 16:45 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine investor presentation update; no M&A indicators present. |
SEC · detail |
| 2026-05-15 16:31 |
8-K |
["1.01", "2.03", "3.02", "9.01"] |
other |
0.05
|
Private placement of convertible notes and warrants; financing activity unrelated to M&A. |
SEC · detail |
| 2026-05-12 16:30 |
8-K |
["5.02", "8.01", "9.01"] |
material agreement |
0.25
|
NexGel acquired assets/licenses from Celularity; board appointments tied to financing, not M&A target signal. |
SEC · detail |
| 2026-04-30 16:49 |
8-K |
["5.02"] |
officer change |
0.62
|
CFO appointment with M&A experience; change of control provisions in employment agreement suggest preparation for potential transaction. |
SEC · detail |
| 2026-04-24 17:15 |
8-K |
["3.01"] |
other |
0.05
|
Nasdaq minimum bid price deficiency notice; delisting risk, not M&A-related. |
SEC · detail |